Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled,...
Dosage and administration
THIS PRODUCT IS FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY. Diphenhydramine hydrochloride in the injectable form is indicated when the oral form is impractical. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT...
Diphenhydramine hydrochloride USP is an antihistamine drug having the chemical name 2-(Diphenylmethoxy)-N,N-dimethylethylamine hydrochloride. It occurs as a white, crystalline powder, is freely soluble in water and alcohol and has a molecular weight of 291.82. The molecular formula is C
17H
21NO • HCI. The structural formula is as follows:
Structure
Diphenhydramine hydrochloride USP in the parenteral form is a sterile, pyrogen-free solution available in a concentration of 50 mg of diphenhydramine hydrochloride USP per mL. The solutions for parenteral use have been adjusted to a pH between 4 and 6.5 with either sodium hydroxide or hydrochloric acid.
CLINICAL PHARMACOLOGY
CLINICAL PHARMACOLOGY SECTION
Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.
Diphenhydramine hydrochloride in the injectable form has a rapid onset of action. Diphenhydramine hydrochloride is widely distributed throughout the body, including the CNS. A portion of the drug is excreted unchanged in the urine, while the rest is metabolized via the liver. Detailed information on the pharmacokinetics of Diphenhydramine Hydrochloride Injection is not available.
INDICATIONS AND USAGE
INDICATIONS & USAGE SECTION
Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical.
Antihistaminic
SPL UNCLASSIFIED SECTION
For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.
Motion sickness
SPL UNCLASSIFIED SECTION
For active treatment of motion sickness.
Antiparkinsonism
SPL UNCLASSIFIED SECTION
For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents.
CONTRAINDICATIONS
CONTRAINDICATIONS SECTION
Use in Neonates or Premature Infants
SPL UNCLASSIFIED SECTION
This drug should
not be used in neonates or premature infants.
Use in Nursing Mothers
SPL UNCLASSIFIED SECTION
Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.
Use as a Local Anesthetic
SPL UNCLASSIFIED SECTION
Because of the risk of local necrosis, this drug should not be used as a local anesthetic.
Antihistamines are also contraindicated in the following conditions
SPL UNCLASSIFIED SECTION
Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.
WARNINGS
WARNINGS SECTION
Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction.
Local necrosis has been associated with the use of subcutaneous or intradermal use of intravenous diphenhydramine hydrochloride injection.
Use in Pediatric Patients
SPL UNCLASSIFIED SECTION
In pediatric patients, especially, antihistamines in
overdosage may cause hallucinations, convulsions, or death.
As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation.
Use in the Elderly (approximately 60 years or older)
SPL UNCLASSIFIED SECTION
Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.
PRECAUTIONS
PRECAUTIONS SECTION
General
GENERAL PRECAUTIONS SECTION
Diphenhydramine hydrochloride has an atropine-like action and, therefore, should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension. Use with caution in patients with lower respiratory disease including asthma.
Information for Patients
INFORMATION FOR PATIENTS SECTION
Patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol.
Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.
Drug Interactions
DRUG INTERACTIONS SECTION
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
Carcinogenesis, Mutagenesis, Impairment of Fertility
CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION
Long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.
Pregnancy
PREGNANCY SECTION
Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Pediatric Use
PEDIATRIC USE SECTION
Diphenhydramine hydrochloride should not be used in neonates and premature infants (see
CONTRAINDICATIONS).
Diphenhydramine hydrochloride injection may diminish mental alertness, or, in the young pediatric patient, cause excitation. Overdosage may cause hallucinations, convulsions, or death (see
WARNINGS and
OVERDOSAGE).
Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms; dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.
Stimulants should not be used.
Vasopressors may be used to treat hypotension.
DOSAGE AND ADMINISTRATION
DOSAGE & ADMINISTRATION SECTION
THIS PRODUCT IS FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY.
Diphenhydramine hydrochloride in the injectable form is indicated when the oral form is impractical.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.
Pediatric Patients, other than premature infants and neonates
SPL UNCLASSIFIED SECTION
5 mg/kg/24 hr or 150 mg/m
2/24 hr. Maximum daily dosage is 300 mg.
Divide into four doses, administered intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly.
Adults
SPL UNCLASSIFIED SECTION
10 to 50 mg intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly, 100 mg if required; maximum daily dosage is 400 mg.
HOW SUPPLIED
HOW SUPPLIED SECTION
Diphenhydramine Hydrochloride Injection, USP in parenteral form is supplied as:
Sterile, pyrogen-free solution containing 50 mg diphenhydramine hydrochloride USP in a 1 mL amber color glass vial with yellow bands and white OPC mark, and available in packages of twenty-five packed in a PVC rondo tray in a single carton.
1 mL fill in 1 mL Vial NDC 72485-101-01
Carton of 25 x 1 mL Vial NDC 72485-101-25
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Protect from freezing and light. Retain in carton until time of use.
Keep this and all drugs out of the reach of children.
Rx only
HIGH POTENCY
Latex Free
Manufactured by: Micro Labs Limited
Bangalore-560 099. INDIA
M. L. No. : KTK/28/357/2006
Distributed by: Armas Pharmaceuticals, Inc.
Manalapan, NJ 07726 (USA)
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.